Phase I: The purpose of this study was to determine which of the subcutaneous doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS~Phase II: To evaluate hematological responses at the dose selected in the Phase I portion of the study.~Note: This study was planned as Phase 1/2 study but only the Phase 1 part was conducted due to a change in product development strategy
The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).